Consensus BioCryst Pharmaceuticals, Inc.

Stocks

BCRX

US09058V1035

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 19:44:39 14/10/2026 +04			5-day change	1st Jan Change
8.095 ^USD	+0.31%		-3.39%	+4.04%

10-05	Biocryst Pharmaceuticals, Inc. Announces Formation of Scientific Advisory Board	CI
10-05	BioCryst Pharmaceuticals Forms Scientific Advisory Board as R&D Model Evolves	MT

Evolution of the Average Target: BioCryst Pharmaceuticals, Inc.

Evolution of the Target Price: BioCryst Pharmaceuticals, Inc.

Changes in Analyst Recommendations: BioCryst Pharmaceuticals, Inc.

b6f65b65447642221e.8aKHipo5q32rgCUkmPigQeugOjqyEfdQRQCqeHQJjrQ.ptrd7-t6_A6G81Bj96v2KYXyb2vHSKRmDTHjSQZW692i5sHi3AmaD_nQTg~6bfa17cf50eb64a553379c2d6eeff50d

Analysts' recommendations: BioCryst Pharmaceuticals, Inc.

09-10	RBC Downgrades BioCryst Pharmaceuticals to Sector Perform From Outperform, Cuts Price Target to $11 From $13	MT
08-06	RBC Adjusts Price Target on BioCryst Pharmaceuticals to $13 From $14, Maintains Outperform Rating	MT
08-05	Wedbush Adjusts BioCryst Pharmaceuticals Price Target to $20 From $21, Maintains Outperform Rating	MT
07-07	RBC Capital Adjusts BioCryst Pharmaceuticals Price Target to $14 From $13, Maintains Outperform Rating	MT
04-07	RBC Capital Adjusts BioCryst Pharmaceuticals PT to $14 From $13, Maintains Outperform Rating	MT
03-25	BioCryst Shares Remain Undervalued, RBC Says	MT
02-27	Wedbush Adjusts Price Target on BioCryst Pharmaceuticals to $22 From $21, Maintains Outperform Rating	MT
01-30	RBC Cuts Price Target on BioCryst Pharmaceuticals to $13 From $14, Keeps Outperform Rating	MT
01-08	RBC Cuts Price Target on BioCryst Pharmaceuticals to $14 From $15, Keeps Outperform Rating	MT
12-30	BioCryst Pharmaceuticals Face Numerous Important Catalysts in 2026, Wedbush Says	MT
15/10/25	RBC Raises Price Target on BioCryst Pharmaceuticals to $15 From $14, Keeps Outperform Rating	MT
08/10/25	RBC Lifts Price Target on BioCryst Pharmaceuticals to $14 From $13, Keeps Outperform Rating	MT
01/10/25	Evercore ISI Downgrades BioCryst Pharmaceuticals to In Line From Outperform, Lifts Price Target to $8 From $12	MT
30/06/25	Wedbush Raises Price Target on BioCryst Pharmaceuticals to $18 From $16, Maintains Outperform Rating	MT
06/05/25	RBC Raises Price Target on BioCryst Pharmaceuticals to $13 From $11, Keeps Outperform Rating	MT
25/02/25	RBC Capital Adjusts Price Target on BioCryst Pharmaceuticals to $11 From $10, Keeps Outperform Rating	MT
07/05/24	JMP Securities Adjusts Price Target on BioCryst Pharmaceuticals to $15 From $14, Maintains Market Outperform Rating	MT
18/09/23	BioCryst Pharmaceuticals Receives Upgrade From RBC to Outperform From Sector Perform, Price Target Raised to $10 From $9	MT
04/08/23	Jefferies Upgrades BioCryst Pharmaceuticals to Buy From Hold, Price Target is $11	MT
04/08/23	RBC Raises Price Target on BioCryst Pharmaceuticals to $9 From $8, Keeps Sector Perform, Speculative Risk	MT
13/07/23	BofA Securities Upgrades BioCryst Pharmaceuticals to Buy From Neutral, Price Target is $10	MT
07/07/23	RBC Trims BioCryst Pharmaceuticals' Price Target to $8 From $9, Keeps Sector Perform Speculative Risk Rating	MT
20/04/23	Evercore ISI Lowers Price Target on BioCryst Pharmaceuticals to $10 From $13, Maintains Outperform Rating	MT
06/04/23	RBC Capital Adjusts BioCryst Pharmaceuticals Price Target to $9 From $10, Maintains Sector Perform - Speculative Risk Rating	MT
22/02/23	Needham Upgrades BioCryst Pharmaceuticals to Buy From Hold With $14 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	BIOCRYST PHARMACEUTICALS, INC.					+156.84%
	WUXI APPTEC CO., LTD.					+21.23%
	ARGENX SE					+41.64%
	LONZA GROUP AG					+21.73%
	IQVIA HOLDINGS INC.					+13.73%
	REVOLUTION MEDICINES, INC.					+37.52%
	BEONE MEDICINES AG					+24.77%
	CELLTRION, INC.					+49.05%
	WUXI BIOLOGICS (CAYMAN) INC.					+16.02%
	BIONTECH SE					+30.78%
	Average					+41.33%
	Weighted average by Cap.					+28.55%